Jin-San Yoo
President, R&D PharmAbcine
- Founder and CEO of PharmAbcine, Inc, PharmAbcine Australia Pty and Wincal BioPharm
- MAB Expert of EDQM
- Member of The National Academy of Engineering of Korea
Seminars
Tuesday 9th June 2026
Analyzing the Development of EGFRvii x MUC1 Bispecific ADC & Its Strategy in Improving Tumor Penetration
9:30 am
- Introducing EGFRviii and MUC1
- Exploring the dual combination of EGFRviii x MUC1
- Discussing better enrichment of ADC into the TME in the presence of vessel normalizer, PMC-403
